Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)-Reference-Cited by-同舟云学术

Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)

Published:2020-06-28 Issue:1 Volume:24 Page:156-167
ISSN:1436-3291
Container-title:Gastric Cancer
language:en
Short-container-title:Gastric Cancer

Author:

Lee Keun-Wook,Chung Ik-Joo,Ryu Min-Hee,Park Young Iee,Nam Byung-Ho,Oh Ho-Suk,Lee Kyung Hee,Han Hye Sook,Seo Bong-Gun,Jo Jae-Cheol,Lee Hyo Rak,Kim Jin Won,Park Sook Ryun,Cho Sang Hee,Kang Yoon-Koo,

Funder

Jeil Pharmaceutical Co., Ltd.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Gastroenterology,Oncology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10120-020-01101-4.pdf

Reference24 articles.

1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–386.

2. Kim JW, Kim JG, Kang BW, Chung IJ, Hong YS, Kim TY, et al. Treatment patterns and changes in quality of life during first-line palliative chemotherapy in korean patients with advanced gastric cancer. Cancer Res Treat. 2019;51:223–39.

3. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–97.